Showing results (51-60 of 192) with videos related to
Sort By:
Pageof 20
Scientific Reports|October 26, 2021
Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosisKathryn Gazelakis, Ammar Majeed, William Kemp, et al.Journal of Digestive Diseases|March 12, 2014
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patientsSteve Lontos, Edward Shelton, Peter W Angus, et al.Journal of Gastroenterology and Hepatology|July 25, 2014
Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in AustraliaWilliam Sievert, Homie Razavi, Chris Estes, et al.Internal Medicine Journal|May 21, 2026
Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost metabolic (dysfunction)-associated fatty liver disease analysis from a tertiary-care, multi-disciplinary MAFLD clinicNatalie Ngu, Karl Vaz, Tobie Abrahams, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2013
Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver diseaseMatthew T Kitson, William W Kemp, David M Iser, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 4, 2004
Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquineSimon A Zanati, Stephen A Locarnini, John P Dowling, et al.Viruses|April 28, 2023
Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital InpatientsChristine Roder, Carl Cosgrave, Kathryn Mackie, et al.Scandinavian Journal of Gastroenterology|April 24, 2012
A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver diseaseStephen P Casey, William W Kemp, Catriona A McLean, et al.Internal Medicine Journal|May 31, 2018
Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalenceElena S George, Stuart K Roberts, Amanda J Nicoll, et al.Hepatology (Baltimore, Md.)|November 18, 2009
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosisSavino Bruno, Mitchell L Shiffman, Stuart K Roberts, et al.Pageof 20